Ritonavir-Boosted Protease Inhibitors/Boceprevir
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Boceprevir may speed up how quickly your liver processes your HIV medicine. Your HIV medicine may speed up how quickly your liver processes boceprevir.
What might happen:
Your medicines may not work as well in treating your HIV and your hepatitis.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together and discuss the risks and benefits of using these medicines together. Your doctor may want to run some tests to see how your medicines are working. Your doctor may want to change your medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Reddy SSK. Dear US Healthcare Professional: SUBJECT: Results of Pharmacokinetic Study in Healthy Volunteers Given VICTRELIS (boceprevir) and Ritonavir-Boosted HIV Protease Inhibitors May Indicate Clinically Significant Drug Interactions for. Patients Coinfected with Chronic Hepatitis C and HIV. Merck & Co., Inc. February 6, 2012.
2.USFood and Drug Administration. FDA Drug Safety Communication: Important drug interactions between Victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs. available at: http://www.fda.gov/Drugs/DrugSafety/ucm291119.htm#HCPs February 8, 2012.
3.USFood and Drug Administration. FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs. available at: http://www.fda.gov/Drugs/DrugSafety/ucm301616.htm April 26, 2012.